<DOC>
	<DOCNO>NCT01809691</DOCNO>
	<brief_summary>The purpose study compare overall survival newly diagnose metastatic prostate cancer patient randomly assign androgen deprivation therapy ( ADT ) + TAK-700 versus ADT + bicalutamide .</brief_summary>
	<brief_title>S1216 , Phase III ADT+TAK-700 vs. ADT+Bicalutamide Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Clinical diagnosis metastatic prostate cancer . Serum testosterone within institutional limit normal . PSA ≥ 2 ng/mL within 90 day prior initiation androgen deprivation . therapy ( early induction ) prior registration ( late induction ) . DEXA scan within 2 year prior registration . ECG within 42 day prior registration QTc interval ≤ 460 msec . LVEF within 42 day prior registration within institutional limit normal . Adequate hepatic function evidence bilirubin ≤ 2 x institutional upper limit normal ( ULN ) , SGOT ( AST ) SGPT ( ALT ) ≤ 3 x institutional ULN , ≤ 5 x institutional ULN liver metastases present . Adequate renal function evidence calculated creatinine clearance ≥ 40 mL/min . Adequate hematologic function evidence leukocyte ≥ 3,000/mcL , absolute neutrophil count ( ANC ) ≥ 1,500/mcL , hemoglobin ≥ 9 g/dL , platelet ≥ 100,000/mcL . Zubrod performance status 0 2 . Zubrod performance status 3 allow bone pain . ≥ 18 year age . Men reproduction potential surgically sterilize ( i.e. , postvasectomy ) must agree practice effective barrier contraception agree abstain intercourse receive treatment study least 4 month protocol treatment end . Known brain metastasis . No 36 month prior neoadjuvant and/or adjuvant hormonal therapy . ≥ 6 month since completion androgen deprivation therapy . Prior concurrent therapy ketoconazole , aminoglutethimide abiraterone acetate , enzalutamide ( MDV3100 ) . Concurrent megestrol hot flash allow . Prior chemotherapy treatment metastatic prostate cancer . Prior chemotherapy neoadjuvant adjuvant setting allow . ≥ 2 year since completion chemotherapy neoadjuvant adjuvant setting . Concurrent use experimental therapy allow . ≥ 30 day since prior medical castration metastatic prostate cancer . If method castration LHRH agonist , patient must willing continue use LHRH add bicalutamide TAK700 protocol treatment . If patient antiandrogen ( e.g . bicalutamide , flutamide ) , patient must willing switch bicalutamide TAK700 ( accord randomization ) . Prior bilateral orchiectomy . Concurrent use LHRH antagonist ( e.g . Degarelix ) Grade III/IV cardiac disease ( define NYHA Criteria ) , thromboembolic event , unstable angina pectoris , myocardial infarction within 6 month , serious uncontrolled cardiac arrhythmia . Uncontrolled hypertension ( define blood pressure &gt; 160 mmHg systolic &gt; 90 mmHg diastolic 2 separate measurement 60 minute apart Screening visit ) despite appropriate medical therapy . Known human immunodeficiency virus ( HIV ) infection , active chronic hepatitis B C , lifethreatening illness unrelated cancer , serious medical psychiatric illness could , investigator 's opinion , potentially interfere participation study . History primary secondary adrenal insufficiency . Hypersensitivity TAK700 , TAK700 metabolites , bicalutamide , LHRH agonists . Gastrointestinal ( GI ) disease GI procedure could interfere GI absorption tolerance TAK700 , include difficulty swallow oral medication . No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>TAK-700</keyword>
	<keyword>Bicalutamide</keyword>
	<keyword>S1216</keyword>
	<keyword>androgen therapy</keyword>
	<keyword>Phase III</keyword>
</DOC>